Clinical Trial Results:
A randomised, double-blind, placebo-controlled, multi-centre Phase I Trial investigating the safety of ALK Grass tablet in children aged 5-12 years with grass pollen induced rhinoconjunctivitis (with/without asthma). – Estudio multicéntrico, randomizado, doble ciego-placebo para evaluar la seguridad de las tabletas ALK Grass, Phleum pratense en niños alérgicos a Gramíneas.
Summary
|
|
EudraCT number |
2005-004962-18 |
Trial protocol |
ES |
Global completion date |
04 May 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Jun 2016
|
First version publication date |
04 Jun 2016
|
Other versions |
|
Summary report(s) |
GT-09 Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.